Vasculitis & polymyalgia rheumatica
The Effect of Intranasal Niclosamide on Nasal Symptoms in Patients with Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Authors' conclusion
These data are a signal of potential clinical effect on ENT manifestations in AAV.
Study context
- Population
- Patients with AAV from a single centre enrolled into the intranasal niclosamide arm of PROTECT-V (COVID-19 pre-exposure prophylaxis platform trial)
- Participants
- 32 patients
- Comparison
- Intranasal niclosamide vs placebo
- Niclosamiden = 14
- Placebon = 18reference
- Primary endpoint
- ENT symptoms
- Follow-up
- During treatment
Methodological detailsdouble-blind, placebo-controlled, platform trial, single-centre subanalysis, retrospective clinical data collection, Researchers blinded to treatment allocation, Median treatment exposure 200 (IQR 109-251) days, Clinical data retrospectively collected for 9 months before, during, and 9 months after treatment
- Double-blind
- Placebo-controlled
- Platform trial
- Single-centre subanalysis
- Retrospective clinical data collection
- Researchers blinded to treatment allocation
- Median treatment exposure 200 (IQR 109-251) days
- Clinical data retrospectively collected for 9 months before, during, and 9 months after treatment
Primary result
As reported in the abstract
P = 0.04
Further findings
| Outcome | Niclosamide | Placebo |
|---|---|---|
| ENT symptoms in PR3-ANCA-positive patients (subgroup) · during treatment | 0 events | 56% |
- Ear, nose, and throat (ENT) symptoms in PR3-ANCA-positive patients (subgroup): 0 of 10 vs 5 of 9
ENT symptoms, 9 months before and after treatment
- No significant difference between groups
Original publication
The Effect of Intranasal Niclosamide on Nasal Symptoms in Patients with Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. Arthritis Rheumatol. Published 23 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →